A pioneering plan is emerging that combines the fields of stem cell science, immunology, and transplantation research with a clear and ambitious objective: to restore insulin-producing beta cells in individuals with type 1 diabetes (T1D) without the need for immunosuppressive drugs.
According to Ferreira, who is at the forefront of this initiative, "These awards support the most promising work that can significantly advance the path to cures for type 1 diabetes." This reflects the vision of Breakthrough T1D, which believes this could be the next significant evolution in T1D treatment.
Engineering Immunity for Beta Cell Protection
Ferreira's expertise lies in modifying the immune system through chimeric antigen receptors (CARs). These engineered receptors are designed to guide regulatory T cells (Tregs) to specific targets within the body. Tregs are vital for regulating immune responses and preventing the destruction seen in T1D, acting as protectors against autoimmune damage.
Collaborating with Ferreira are two notable experts: Holger Russ, Ph.D., a leading figure in stem cell research at the University of Florida, and Michael Brehm, Ph.D., from the University of Massachusetts Medical School, who specializes in humanized mouse models for studying immune responses in T1D.
Understanding Type 1 Diabetes
T1D is an autoimmune disorder where the immune system erroneously attacks the insulin-producing beta cells in the pancreas, leading to difficulties in regulating blood sugar levels. Patients must continuously monitor their glucose and rely on insulin injections. Currently, around 1.5 million Americans are affected by this condition.
The Breakthrough T1D award builds on prior funding from the South Carolina Clinical & Translational Research Institute, which initially fostered collaboration between Ferreira and Russ, laying the foundation for this transformative project.
A Two-Part Cellular Therapy Approach
In T1D, the immune system fails to recognize beta cells as part of the body, resulting in their destruction. For patients with severe cases, islet cell transplants are an option, but they face challenges such as a shortage of donor tissue and the risk of immune rejection.
To tackle these issues, the research team is working on producing stem cell-derived islet cells in the lab. Ferreira's immune engineering skills are crucial here; he modifies Tregs with a CAR to target specific proteins on beta cells, effectively guiding these cells to protect the transplanted beta cells from immune attacks.
Eliminating the Need for Immunosuppressive Drugs
This innovative therapy could potentially remove the need for immunosuppressive drugs, which are often necessary after transplants and carry significant long-term risks. The lab-produced beta cells may also resolve the ongoing shortage of donor tissue, offering a scalable solution for future treatments.
The ultimate goal is to create a comprehensive therapy combining engineered Tregs with lab-grown beta cells, making it widely accessible for all individuals with T1D, including those who have lived with the disease for years.
Exploring Long-Term Efficacy
Transitioning this therapy into clinical practice will require extensive research to address crucial questions about the longevity of its protective effects. Initial studies have shown benefits lasting up to a month, and further funding will facilitate exploration into extending these effects and improving delivery methods.
This research not only aims to revolutionize T1D treatment but could also set a precedent in regenerative medicine and immune therapies, fundamentally changing how we approach medical treatment.
"We're striving to replace the missing cells rather than just treating symptoms," Ferreira expressed, highlighting the transformative potential of this groundbreaking work.
